Neuroscientific Biopharmaceuticals Ltd
NSB.AX is a biotechnology company focused on healthcare diagnostics, primarily generating revenue through the development and commercialization of diagnostic products and services.
Business. NSB.AX is a biotechnology and medical research company focused on healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, generating revenue through product sales. Specific details regarding operating segments, headquarters location, and primary exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment breakdowns.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
NSB.AX is a biotechnology and medical research company focused on healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, generating revenue through product sales. Specific details regarding operating segments, headquarters location, and primary exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment breakdowns.
NSB.AX maintains a strong liquidity position, with a current ratio of 49.56, indicating a significant excess of current assets over current liabilities. The company's price-to-book ratio of 1.98 suggests that the market values the company at nearly twice its book value, which may reflect expectations of future growth or intangible assets. However, the company's price-to-tangible-book ratio is also 1.98, indicating that the premium is not attributable to intangible assets.
In terms of profitability, NSB.AX reported a net loss of -1,845,510 AUD and an operating loss of -1,843,050 AUD, resulting in a negative return on equity of -10.98% and a negative return on assets of -10.88%. These figures are significantly below the industry median for profitability metrics, suggesting that the company is underperforming relative to its peers in terms of generating returns.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification reported. This lack of diversification may expose the company to higher risks if demand in its primary market declines or if regulatory changes impact its operations.
Looking at the company's growth trajectory, there is no recent data provided on revenue growth or future projections. The company's operating cash flow is negative at -941,330 AUD, and its free cash flow is also negative at -1,752,730 AUD, indicating that the company is not generating sufficient cash from operations to fund its activities. This suggests that the company may need to rely on external financing or asset sales to sustain operations in the near term.
The risk assessment for NSB.AX indicates a low level of liquidity risk and a low probability of dilution in the near term. The company has no long-term debt and a high cash balance of 7,265,770 AUD, which provides a buffer against short-term financial obligations. There are no immediate filing-based liquidity or dilution flags, suggesting that the company is not currently facing significant financial distress.
Recent events and filings do not indicate any major changes in the company's financial position or strategic direction. The company's financial statements do not mention any recent acquisitions, divestitures, or significant legal proceedings that could impact its operations or financial health.
- NSB.AX has a strong liquidity position with a current ratio of 49.56.
- The company is currently unprofitable, with a net loss of -1,845,510 AUD and a negative return on equity of -10.98%.
- NSB.AX's revenue is concentrated in a single business segment, with no geographic diversification reported.
- The company has a high cash balance of 7,265,770 AUD, which provides a buffer against short-term financial obligations.
- NSB.AX is not generating positive operating or free cash flow, indicating a need for external financing or asset sales to sustain operations.
- **margin_outlook_rationale**: The company's negative net income and operating income suggest a deteriorating margin outlook driven by high operating costs and low revenue.
- **rd_outlook_rationale**: No specific R&D outlook is provided, but the company's focus on healthcare diagnostics implies ongoing investment in research and development.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- NSB.AX Market data — financials · 2026-05-28